{"content":"<li class=\"n-box-item date-title\" data-end=\"1476158399\" data-start=\"1476072000\" data-txt=\"Sunday, December 22, 2019\">Monday, October 10, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3213251\" data-ts=\"1476139655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213251-reuters-moonves-want-autonomy-to-control-merged-cbs-viacom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Moonves would want autonomy to control merged CBS/Viacom</a></h4><ul>   <li>If CBS (<a href=\"https://seekingalpha.com/symbol/CBS\" title=\"CBS Corporation\">CBS</a> <font color=\"green\">+0.9%</font>) ends up in any remarriage with Viacom (<a href=\"https://seekingalpha.com/symbol/VIA\" title=\"Viacom Inc.\">VIA</a> <font color=\"green\">+0.1%</font>, <a href=\"https://seekingalpha.com/symbol/VIAB\" title=\"Viacom Inc.\">VIAB</a>) -- and the rumblings for that get a touch louder every week -- CBS chief Les Moonves would <a href=\"http://www.reuters.com/article/us-cbs-corp-viacom-moonves-idUSKCN12A2H5\" target=\"_blank\">push for autonomy from the Redstones</a> in running the combination, Reuters reports.</li>    <li>Sumner Redstone controls both companies with 80% voting rights through his holdings at National Amusements, and that level of independence may be a tough sell. Negotiations haven't begun in any serious manner.</li>    <li>But sources told Reuters that Moonves would try to capitalize on a decade-long track record of success at CBS. Moonves is reportedly going over his options with Wall Street lawyer Martin Lipton, whose firm has advised CBS for years.</li>    <li>When CBS merged with Viacom the first time, in 2000, its bylaws gave then-president Mel Karmazin full operating control, and a clause that required three-quarters of the board to fire him. He later resigned over differences with Redstone.</li>    <li>The two companies have <a href=\"https://seekingalpha.com/news/3211827-wsj-cbs-viacom-setting-committees-ponder-merger\" target=\"_blank\">formed independent board committees</a> and <a href=\"https://seekingalpha.com/news/3213045-wsj-viacom-cbs-hire-advisers-consider-merger\" target=\"_blank\">hired advisers</a> as they consider a request from the Redstones to look into a merger.</li>    <li>After hours: <a href=\"https://seekingalpha.com/symbol/VIAB\" title=\"Viacom Inc.\">VIAB</a> <font color=\"green\">+2%</font>; <a href=\"https://seekingalpha.com/symbol/VIA\" title=\"Viacom Inc.\">VIA</a> <font color=\"green\">+0.5%</font>.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3211896-ad-buyers-show-enthusiasm-prospect-cbs-viacom-combo\" target=\"_blank\">Ad buyers show enthusiasm at prospect of CBS/Viacom combo</a> (Sep. 30 2016)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3211870-viacom-committee-examining-cbs-merger-heavy-new-members\" target=\"_blank\">Viacom committee examining CBS merger is heavy on new members</a> (Sep. 30 2016)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213251\" data-linked=\"Reuters: Moonves would want autonomy to control merged CBS/Viacom\" data-tweet=\"$VIA $VIA $VIAB - Reuters: Moonves would want autonomy to control merged CBS/Viacom https://seekingalpha.com/news/3213251-reuters-moonves-want-autonomy-to-control-merged-cbs-viacom?source=tweet\" data-url=\"https://seekingalpha.com/news/3213251-reuters-moonves-want-autonomy-to-control-merged-cbs-viacom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213244\" data-ts=\"1476135587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213244-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> EBIO <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/CNHI' title='CNH Industrial N.V.'>CNHI</a> <font color='green'>+1.8%</font>. <a href='https://seekingalpha.com/symbol/CVGI' title='Commercial Vehicle Group, Inc.'>CVGI</a> <font color='green'>+1.6%</font>. <a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a> <font color='green'>+1.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a> <font color='red'>-22.9%</font>. <a href='https://seekingalpha.com/symbol/PAC' title='Grupo Aeroportuario del Pacifico, S.A.B de C.V.'>PAC</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a> <font color='red'>-2.4%</font>. <a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a> <font color='red'>-2.3%</font>. <a href='https://seekingalpha.com/symbol/TMO' title='Thermo Fisher Scientific Inc.'>TMO</a> <font color='red'>-1.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213244\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$SESN $PIR $CNHI - After Hours Gainers / Losers https://seekingalpha.com/news/3213244-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3213244-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213234\" data-ts=\"1476131694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LC\" target=\"_blank\">LC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213234-lending-clubminus-4-after-hours-on-ugly-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lending Club -4% after hours on &#39;ugly note&#39;</a></h4><ul>\n<li>In an \"ugly note,\" Wedbush has initiated coverage of Lending Club (NYSE:<a href=\"https://seekingalpha.com/symbol/LC\" title=\"LendingClub Corporation\">LC</a>) with an Underperform and $3.75 price target.</li>\n<li><a href=\"https://twitter.com/markflowchatter/status/785575249064624128\" target=\"_blank\">via Marc Lehman</a></li>\n<li>Shares <font color=\"red\">-4%</font> after hours to $5.80.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213234\" data-linked=\"Lending Club -4% after hours on &#39;ugly note&#39;\" data-tweet=\"$LC - Lending Club -4% after hours on &#39;ugly note&#39; https://seekingalpha.com/news/3213234-lending-clubminus-4-after-hours-on-ugly-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3213234-lending-clubminus-4-after-hours-on-ugly-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213226\" data-ts=\"1476130551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213226-reuters-salesforce-still-considering-twitter-bid-despite-resistance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Salesforce still considering Twitter bid despite resistance</a></h4><ul>\n<li>Although Salesforce was <a href=\"https://seekingalpha.com/news/3213125-twitter-minus-13_55-percent-pre-market-salesforce-bid-reported-unlikely\" target=\"_blank\">thought to be out of the mix</a> as of this weekend, a new <a href=\"http://www.reuters.com/article/us-twitter-m-a-salesforce-com-idUSKCN12A2B2\" target=\"_blank\">report</a> has the company nonetheless still evaluating the benefits a deal could represent and what an appropriate valuation surrounding one might be.</li>\n<li>Potentially lowball offer cited to be under deliberation.</li>\n<li>Meanwhile, in an internal memo <a href=\"https://www.bloomberg.com/news/articles/2016-10-10/twitter-s-dorsey-rallies-staff-around-independent-strategy-in-internal-memo\" target=\"_blank\">reportedly</a> sent out to Twitter employees last week, CEO Jack Dorsey made no mention of any deals, instead highlighting initiatives revolving around the company's live strategy and other merits.</li>\n<li>Twitter (NYSE:<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a>) <font color=\"green\">+0.63%</font> after hours, Salesforce (NYSE:<a href=\"https://seekingalpha.com/symbol/CRM\" title=\"Salesforce.com, Inc.\">CRM</a>) <font color=\"red\">-0.25%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213226\" data-linked=\"Reuters: Salesforce still considering Twitter bid despite resistance\" data-tweet=\"$TWTR $TWTR $CRM - Reuters: Salesforce still considering Twitter bid despite resistance https://seekingalpha.com/news/3213226-reuters-salesforce-still-considering-twitter-bid-despite-resistance?source=tweet\" data-url=\"https://seekingalpha.com/news/3213226-reuters-salesforce-still-considering-twitter-bid-despite-resistance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213223\" data-ts=\"1476130160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213223-myriad-genetics-eases-12-on-potential-soft-demand-for-companion-diagnostics-in-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad Genetics eases 12% on potential soft demand for companion diagnostics in cancer</a></h4><ul><li>Myriad Genetics (<a href=\"https://seekingalpha.com/symbol/MYGN\" title=\"Myriad Genetics, Inc.\">MYGN</a> <font color=\"red\">-11.6%</font>) couldn't find a friend today despite the market's up move. Shares were down on 33% higher volume. The <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/10/8546494/what-tesaros-phase-3-nova-results-mean-for-myriad-geneti\" target=\"_blank\">bearishness </a>appears to have arisen from TESARO's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/TSRO\" title=\"Tesaro\">TSRO</a>) successful Phase 3 study of niraparib in ovarian cancer. The drug extended progression-free survival regardless of BRCA status thereby undermining the need for a companion diagnostic test like Myriad's <a href=\"https://www.myriad.com/mychoice-hrd-infographic/\" target=\"_blank\">myChoice HRD</a>. If this portends a broader trend in oncology, then there may not be much long-term demand for companion diagnostics.</li></ul><div class=\"tiny-share-widget\" data-id=\"3213223\" data-linked=\"Myriad Genetics eases 12% on potential soft demand for companion diagnostics in cancer\" data-tweet=\"$MYGN $MYGN $TSRO - Myriad Genetics eases 12% on potential soft demand for companion diagnostics in cancer https://seekingalpha.com/news/3213223-myriad-genetics-eases-12-on-potential-soft-demand-for-companion-diagnostics-in-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3213223-myriad-genetics-eases-12-on-potential-soft-demand-for-companion-diagnostics-in-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213225\" data-ts=\"1476129571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPM\" target=\"_blank\">EPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213225-evolution-petroleum-initiated-sector-outperform-scotia-howard-weil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolution Petroleum initiated at Sector Outperform at Scotia Howard Weil</a></h4><ul>     <li>Evolution Petroleum (<a href=\"https://seekingalpha.com/symbol/EPM\" title=\"Evolution Petroleum Corporation\">EPM</a> <font color=\"green\">+7.3%</font>) is initiated with a <a href=\"http://www.streetinsider.com/New+Coverage/Scotia+Howard+Weil+Starts+Evolution+Petroleum+%28EPM%29+at+Outperform/12117180.html\" target=\"_blank\">Sector Outperform</a> rating and a $10 price target at Scotia Howard Weil, which notes EPM does not have any shale acreage but has a very oily and stable production profile.</li>     <li>Despite its flawless balance sheet and steady production, Weil says EPM trades around its proved reserve value at $60 oil plus cash, and a stable dividend provides a return to shareholders despite low oil  prices.</li>     <li>EPM has positioned itself to either buy additional cash flowing assets or increase its dividend even at current strip prices, the firm says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213225\" data-linked=\"Evolution Petroleum initiated at Sector Outperform at Scotia Howard Weil\" data-tweet=\"$EPM - Evolution Petroleum initiated at Sector Outperform at Scotia Howard Weil https://seekingalpha.com/news/3213225-evolution-petroleum-initiated-sector-outperform-scotia-howard-weil?source=tweet\" data-url=\"https://seekingalpha.com/news/3213225-evolution-petroleum-initiated-sector-outperform-scotia-howard-weil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213213\" data-ts=\"1476127557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213213-rio-tinto-says-simandou-iron-ore-partner-ifc-to-sell-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto says Simandou iron ore partner IFC to sell stake</a></h4><ul>     <li>Rio Tinto (<a href=\"https://seekingalpha.com/symbol/RIO\" title=\"Rio Tinto plc\">RIO</a> <font color=\"green\">+1.7%</font>) says the World Bank's International Finance Corporation, a partner in its $20B Simandou iron ore project in Guinea, is <a href=\"http://www.reuters.com/article/us-guinea-mining-simandou-idUSKCN12A276\" target=\"_blank\">selling its 4.6% stake</a>.</li>\n<li>The IFC's exit is  the latest setback for the project to develop the world's biggest  untapped iron ore reserves; in July, Rio CEO shelved the project temporarily due to a sustained slump in prices.</li>     <li>Rio owns a 46.6% in the project; China's Chinalco has 41.3% and the Guinea government has 7.5%.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213213\" data-linked=\"Rio Tinto says Simandou iron ore partner IFC to sell stake\" data-tweet=\"$RIO - Rio Tinto says Simandou iron ore partner IFC to sell stake https://seekingalpha.com/news/3213213-rio-tinto-says-simandou-iron-ore-partner-ifc-to-sell-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3213213-rio-tinto-says-simandou-iron-ore-partner-ifc-to-sell-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213211\" data-ts=\"1476126006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213211-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MOBL' title='MobileIron, Inc.'>MOBL</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/MGT' title='MGT Capital Investments Inc'>MGT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/PCYG' title='Park City Group, Inc.'>PCYG</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MDSY' title='ModSys International Ltd.'>OTC:MDSY</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='red'>-9%</font>. MSDI <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213211\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$MOBL $MGT $PCYG - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3213211-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3213211-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213209\" data-ts=\"1476125259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WLL\" target=\"_blank\">WLL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213209-whiting-petroleum-double-suntrust-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whiting Petroleum could double, SunTrust analyst says</a></h4><ul>     <li>Whiting Petroleum (<a href=\"https://seekingalpha.com/symbol/WLL\" title=\"Whiting Petroleum Corporation\">WLL</a> <font color=\"green\">+3.6%</font>) is named SunTrust\u2019s <a href=\"http://blogs.barrons.com/stockstowatchtoday/2016/10/10/why-whiting-petroleum-could-double/\" target=\"_blank\">top pick among E&amp;P companies</a>, as analyst Neal Dingmann writes that WLL should be a big beneficiary of higher commodity prices toward $50/bbl given that the stock was trading in the mid-30\u2019s the last time oil was above $50.</li>     <li>Dingmann points to \"material documented operational strides\" at WLL that should result in solid sustained future production growth, including ~10% pro-forma sequential growth next year, and several difficult financial steps that should enable more efficient earnings growth.</li>\n<li>The firm raises its stock price target to $20 from $18, derived from its 2017 EBITDA estimate of $1.2B vs. $1.1B prior and $900M Wall Street consensus applied to its 9.3x premium to peer group average price target multiple.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213209\" data-linked=\"Whiting Petroleum could double, SunTrust analyst says\" data-tweet=\"$WLL - Whiting Petroleum could double, SunTrust analyst says https://seekingalpha.com/news/3213209-whiting-petroleum-double-suntrust-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3213209-whiting-petroleum-double-suntrust-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213208\" data-ts=\"1476125131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213208-jd-com-target-raised-suntrust-robinson-humphrey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com target raised at SunTrust Robinson Humphrey</a></h4><ul>\n<li>Analyst Robert Peck sets a $31 target, up from $27 previously (current price $27.34).</li>\n<li>Last week, Wal-Mart Stores <a href=\"https://seekingalpha.com/news/3212614-wal-mart-stores-raises-jd-com-stake-10_8-percent\" target=\"_blank\">raised its stake</a> in JD.com (<a href=\"https://seekingalpha.com/symbol/JD\" title=\"JD.com\">JD</a> <font color=\"green\">+1.1%</font>) from 5.9% to 10.8%, a development which Peck anticipates JD.com to explore the impact of during its Q3 earnings next month, along with other matters noted <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/10/8546012/expect-an-in-line-quarter-from-jd-com\" target=\"_blank\">here</a>.</li>\n<li>Buy rating restated.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213208\" data-linked=\"JD.com target raised at SunTrust Robinson Humphrey\" data-tweet=\"$JD - JD.com target raised at SunTrust Robinson Humphrey https://seekingalpha.com/news/3213208-jd-com-target-raised-suntrust-robinson-humphrey?source=tweet\" data-url=\"https://seekingalpha.com/news/3213208-jd-com-target-raised-suntrust-robinson-humphrey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213205\" data-ts=\"1476124798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWSV\" target=\"_blank\">GWSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213205-bottled-water-microcapplus-85-after-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bottled water microcap +85% after buyout</a></h4><ul> <li>Glacier Water Services (<a href=\"https://seekingalpha.com/symbol/GWSV\" title=\"Glacier Water Services, Inc.\">OTCPK:GWSV</a>) is <font color=\"green\">up 85%</font> after the company was acquired by Primo Water earlier today in deal valued at around $263M.</li> <li>The company operates 23.4K water and ice vending machines in the U.S. and Canada.</li> <li>The microcap stock is traded on the OTC Markets.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3213144-big-pop-primo-water-landing-glacier-water\" target=\"_blank\">Big pop for Primo Water after landing Glacier Water</a> (Oct. 10)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213205\" data-linked=\"Bottled water microcap +85% after buyout\" data-tweet=\"$GWSV - Bottled water microcap +85% after buyout https://seekingalpha.com/news/3213205-bottled-water-microcapplus-85-after-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3213205-bottled-water-microcapplus-85-after-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213203\" data-ts=\"1476124349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213203-national-beverage-corp-higher-amid-sector-m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage Corp. higher amid sector M&amp;A</a></h4><ul> <li>Shares of National Beverage Corp. (<a href=\"https://seekingalpha.com/symbol/FIZZ\" title=\"National Beverage Corp.\">FIZZ</a> <font color=\"green\">+6.8%</font>) rally with some M&amp;A activity taking place in the beverage sector.</li> <li>Earlier today, Primo Water <a href=\"https://seekingalpha.com/news/3213144-big-pop-primo-water-landing-glacier-water\" target=\"_blank\">acquired</a> Glacier Water Services for ~$263M.</li> <li>Volatility on FIZZ has been high since a short report was issued by Glaucus Research. Several <a href=\"https://seekingalpha.com/symbol/FIZZ/focus\" target=\"_blank\">SA contributors</a> think the Glaucus attack reaches too far.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213203\" data-linked=\"National Beverage Corp. higher amid sector M&amp;A\" data-tweet=\"$FIZZ - National Beverage Corp. higher amid sector M&amp;A https://seekingalpha.com/news/3213203-national-beverage-corp-higher-amid-sector-m?source=tweet\" data-url=\"https://seekingalpha.com/news/3213203-national-beverage-corp-higher-amid-sector-m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213200\" data-ts=\"1476123546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RT\" target=\"_blank\">RT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213200-ruby-tuesday-recovers-after-post-earnings-swoon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ruby Tuesday recovers after post-earnings swoon</a></h4><ul> <li>Ruby Tuesday (NYSE:<a href=\"https://seekingalpha.com/symbol/RT\" title=\"Ruby Tuesday, Inc.\">RT</a>) is bouncing strongly off the 52-week low it saw in on Friday after earnings disappointed.</li> <li>Investors are marching to their own drummer today, without any major analysts upgrades behind the rally.</li> <li>Shares of Ruby Tuesday are <font color=\"green\">up 8.96%</font> to $2.56 vs. a 52-week trading range of $2.08 to $6.00.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3212839-ruby-tuesday-eps-line\" target=\"_blank\">Ruby Tuesday EPS in-line</a> (Oct. 6)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3212942-ruby-tuesday-lower-posting-soft-sales\" target=\"_blank\">Ruby Tuesday lower after posting soft sales</a> (Oct. 7)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213200\" data-linked=\"Ruby Tuesday recovers after post-earnings swoon\" data-tweet=\"$RT - Ruby Tuesday recovers after post-earnings swoon https://seekingalpha.com/news/3213200-ruby-tuesday-recovers-after-post-earnings-swoon?source=tweet\" data-url=\"https://seekingalpha.com/news/3213200-ruby-tuesday-recovers-after-post-earnings-swoon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213196\" data-ts=\"1476122524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213196-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul> <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/SAEX\" title=\"SAExploration Holdings, Inc.\">SAEX</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/AREX\" title=\"Approach Resources Inc.\">AREX</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/FANG\" title=\"Diamondback Energy\">FANG</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/PQ\" title=\"PetroQuest Energy Inc.\">PQ</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/USEG\" title=\"U.S. Energy Corp.\">USEG</a> <font color=\"green\">+11%</font>.</li> <li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/AMTX\" title=\"Aemetis, Inc.\">AMTX</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/GSV\" title=\"Gold Standard Ventures\">GSV</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/LTBR\" title=\"Lightbridge Corp\">LTBR</a> <font color=\"red\">-5%</font>. <a href=\"https://seekingalpha.com/symbol/ZN\" title=\"Zion Oil &amp; Gas Inc\">ZN</a> <font color=\"red\">-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213196\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$SAEX $AREX $FANG - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3213196-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3213196-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213191\" data-ts=\"1476118965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213191-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corp'>AAMC</a> <font color='green'>+11%</font>. WAC <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/IMH' title='Impac Mortgage Holdings, Inc.'>IMH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AIII' title='ACRE Realty Investors Inc.'>AIII</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3213191\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$AAMC $DHCP $IMH - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3213191-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3213191-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213186\" data-ts=\"1476117919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213186-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/EGAS\" title=\"Gas Natural Inc.\">EGAS</a> <font color=\"green\">+64%</font>. MCUR <font color=\"green\">+32%</font>. <a href=\"https://seekingalpha.com/symbol/TSRO\" title=\"Tesaro\">TSRO</a> <font color=\"green\">+23%</font>. <a href=\"https://seekingalpha.com/symbol/MOBL\" title=\"MobileIron, Inc.\">MOBL</a> <font color=\"green\">+19%</font>. <a href=\"https://seekingalpha.com/symbol/SAEX\" title=\"SAExploration Holdings, Inc.\">SAEX</a> <font color=\"green\">+19%</font>. <a href=\"https://seekingalpha.com/symbol/IPCI\" title=\"IntelliPharmaCeutics International Inc\">IPCI</a> <font color=\"green\">+19%</font>. <a href=\"https://seekingalpha.com/symbol/MZOR\" title=\"Mazor Robotics Ltd.\">MZOR</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/MGT\" title=\"MGT Capital Investments Inc\">MGT</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/PRMW\" title=\"Primo Water\">PRMW</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/AREX\" title=\"Approach Resources Inc.\">AREX</a> <font color=\"green\">+13%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/FSNN\" title=\"Fusion Connect, Inc.\">FSNN</a> <font color=\"red\">-18%</font>. <a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a> <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/TWLO\" title=\"Twilio\">TWLO</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/AMTX\" title=\"Aemetis, Inc.\">AMTX</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/MYGN\" title=\"Myriad Genetics, Inc.\">MYGN</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/IDSA\" title=\"Industrial Services of America, Inc.\">IDSA</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a> <font color=\"red\">-10%</font>. PSDV <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/HVT\" title=\"Haverty Furniture Companies Inc.\">HVT</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/PHMD\" title=\"PhotoMedex, Inc.\">PHMD</a> <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213186\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$EGAS $LPTX $TSRO - Midday Gainers / Losers https://seekingalpha.com/news/3213186-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3213186-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213183\" data-ts=\"1476117270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYT\" target=\"_blank\">SYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213183-syngenta-says-chemchina-financing-is-committed-and-irrevocable\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syngenta says ChemChina financing is &quot;committed and irrevocable&quot;</a></h4><ul>     <li>Bridge financing is \"<a href=\"http://www.reuters.com/article/us-syngenta-m-a-chemchina-idUSKCN12A1SV\" target=\"_blank\">committed and irrevocable</a>\" for ChemChina's $43B takeover of Syngenta (<a href='https://seekingalpha.com/symbol/SYT' title='Syngenta AG'>SYT</a> <font color='red'>-1.5%</font>), the Swiss company says following a report on Chinese news outlet Caixin that the acquisition had hit a snag as a $15B piece of the deal's funding remains missing.</li>     <li>ChemChina is borrowing heavily to buy SYT as China seeks new agricultural technology to bolster its growing population's food supply.</li></ul><div class=\"tiny-share-widget\" data-id=\"3213183\" data-linked=\"Syngenta says ChemChina financing is &quot;committed and irrevocable&quot;\" data-tweet=\"$SYT - Syngenta says ChemChina financing is &quot;committed and irrevocable&quot; https://seekingalpha.com/news/3213183-syngenta-says-chemchina-financing-is-committed-and-irrevocable?source=tweet\" data-url=\"https://seekingalpha.com/news/3213183-syngenta-says-chemchina-financing-is-committed-and-irrevocable\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213181\" data-ts=\"1476116967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALGT\" target=\"_blank\">ALGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213181-no-worry-on-oil-prices-in-airline-sector-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No worry on oil prices in the airline sector today</a></h4><ul> <li>Airlines stocks are higher as investors shrug off the move higher in oil prices.</li> <li>The rally is just ahead of more data dumps from the sector, including key traffic and earnings reports.</li> <li>Gainers include Allegiant Travel (<a href=\"https://seekingalpha.com/symbol/ALGT\" title=\"Allegiant Travel Company\">ALGT</a> <font color=\"green\">+2.5%</font>), Southwest Airlines (<a href=\"https://seekingalpha.com/symbol/LUV\" title=\"Southwest Airlines Co.\">LUV</a> <font color=\"green\">+2.7%</font>), United Continental (<a href=\"https://seekingalpha.com/symbol/UAL\" title=\"United Continental Holdings, Inc\">UAL</a> <font color=\"green\">+2.3%</font>), American Airlines Group (<a href=\"https://seekingalpha.com/symbol/AAL\" title=\"American Airlines Group\">AAL</a> <font color=\"green\">+2.2%</font>), SkyWest (<a href=\"https://seekingalpha.com/symbol/SKYW\" title=\"SkyWest, Inc.\">SKYW</a> <font color=\"green\">+2.1%</font>), and JetBlue (<a href=\"https://seekingalpha.com/symbol/JBLU\" title=\"JetBlue Airways Corporation\">JBLU</a> <font color=\"green\">+2.1%</font>).</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3213149-crude-oil-rallies-putin-says-russia-ready-join-production-deal\" target=\"_blank\">Crude oil rallies as Putin says Russia is ready to join production deal</a> (Oct. 10)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213181\" data-linked=\"No worry on oil prices in the airline sector today\" data-tweet=\"$ALGT $ALGT $LUV - No worry on oil prices in the airline sector today https://seekingalpha.com/news/3213181-no-worry-on-oil-prices-in-airline-sector-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3213181-no-worry-on-oil-prices-in-airline-sector-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213178\" data-ts=\"1476116549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213178-fda-tentatively-oks-intellipharmaceutics-generic-seroquel-xr-shares-up-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA tentatively OKs Intellipharmaceutics&#39; generic Seroquel XR; shares up 19%</a></h4><ul>\n<li>The FDA grants tentative approval for Intellipharmaceutics' (<a href=\"https://seekingalpha.com/symbol/IPCI\" title=\"IntelliPharmaCeutics International Inc\">IPCI</a> <font color=\"green\">+18.5%</font>) generic version of AstraZeneca's (<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a> <font color=\"red\">-0.6%</font>) <a href=\"https://www.seroquelxr.com/?source=SERC32979&amp;WT.mc_id=SERC32979&amp;umedium=Paid%20Search&amp;uadpub=Google&amp;ucampaign=Seroquel%20XR%20Branded%20General&amp;ucreative=Seroquel%20XR%20&amp;uplace=seroquel%20xr&amp;device=d&amp;gclid=CO_AhL_Q0M8CFQgxaQodUYwBVg&amp;gclsrc=aw.ds#isi_approved\" target=\"_blank\">Seroquel XR</a> (quetiapine fumarate), an oral antipsychotic medicine indicated for the treatment of schizophrenia and manic/mixed episodes associated with bipolar disorder.</li>\n<li>The approval is tentative because the company cannot launch the product until November 1 pursuant to a July 2012 settlement agreement with AstraZeneca. Also, there are two other companies with first-to-file status that may launch their versions on the same date. There is a 180-day exclusivity period related to first-to-file so Intellipharmaceutics' launch may be delayed until after this period.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213178\" data-linked=\"FDA tentatively OKs Intellipharmaceutics&#39; generic Seroquel XR; shares up 19%\" data-tweet=\"$IPCI $IPCI $AZN - FDA tentatively OKs Intellipharmaceutics&#39; generic Seroquel XR; shares up 19% https://seekingalpha.com/news/3213178-fda-tentatively-oks-intellipharmaceutics-generic-seroquel-xr-shares-up-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3213178-fda-tentatively-oks-intellipharmaceutics-generic-seroquel-xr-shares-up-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213179\" data-ts=\"1476116271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213179-europe-finishes-trading-on-high-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Europe finishes trading on a high note</a></h4><ul>     <li>Europe stocks finished the day in positive territory.</li>     <li>The French CAC was <font color='green'>up 1.06%</font> and the German DAX finished with a <font color='green'>1.27% gain</font>. The FTSE 100 was <font color='green'>up 0.75%</font> to finish at its highest level in more than a year. Miners and oil stocks were strong on the day.</li> <li>ETFs: <a href='https://seekingalpha.com/symbol/EWG' title='iShares MSCI Germany ETF'>EWG</a>, <a href='https://seekingalpha.com/symbol/EWI' title='iShares MSCI Italy Capped ETF'>EWI</a>, <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/DAX' title='Recon Capital DAX Germany ETF'>DAX</a>, <a href='https://seekingalpha.com/symbol/GF' title='New Germany Fund'>GF</a>, <a href='https://seekingalpha.com/symbol/EWQ' title='iShares MSCI France ETF'>EWQ</a>, <a href='https://seekingalpha.com/symbol/DXGE' title='WisdomTree Germany Hedged Equity ETF'>DXGE</a>, <a href='https://seekingalpha.com/symbol/DBGR' title='Deutsche X-trackers MSCI Germany Hedged Equity ETF'>DBGR</a>, <a href='https://seekingalpha.com/symbol/HEWG' title='iShares Currency Hedged MSCI Germany ETF'>HEWG</a>, <a href='https://seekingalpha.com/symbol/EWGS' title='iShares MSCI Germany Small Cap Index ETF'>EWGS</a>, <a href='https://seekingalpha.com/symbol/FGM' title='First Trust Germany AlphaDex ETF'>FGM</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/DXPS' title='WisdomTree United Kingdom Hedged Equity ETF'>DXPS</a>, <a href='https://seekingalpha.com/symbol/QDEU' title='SPDR MSCI Germany Quality Mix ETF'>QDEU</a>, <a href='https://seekingalpha.com/symbol/DBUK' title='Deutsche X-trackers MSCI United Kingdom Hedged Equity ETF'>DBUK</a>, <a href='https://seekingalpha.com/symbol/QGBR' title='SPDR MSCI United Kingdom Quality Mix ETF'>QGBR</a>, <a href='https://seekingalpha.com/symbol/HEWI' title='iShares Currency Hedged MSCI Italy ETF'>HEWI</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/DBIT' title='Deutsche X-trackers MSCI Italy Hedged Equity ETF'>DBIT</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213179\" data-linked=\"Europe finishes trading on a high note\" data-tweet=\"$EWG $EWI $EWU - Europe finishes trading on a high note https://seekingalpha.com/news/3213179-europe-finishes-trading-on-high-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3213179-europe-finishes-trading-on-high-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213168\" data-ts=\"1476115804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSNLF\" target=\"_blank\">SSNLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213168-appleplus-2-samsungs-difficulties-escalate-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple +2%, Samsung&#39;s difficulties escalate [updated]</a></h4><ul>\n<li>Having <a href=\"https://seekingalpha.com/news/3213078-report-samsung-suspends-production-note-7\" target=\"_blank\">suspended Galaxy Note 7 production</a> on alleged <a href=\"https://seekingalpha.com/news/3212567-claimed-replacement-samsung-galaxy-note-7-overheats-causes-plane-evacuation\" target=\"_blank\">replacement device issues</a>, Samsung Electronics (<a href=\"https://seekingalpha.com/symbol/SSNLF\" title=\"Samsung Electronics Co., Ltd.\">OTC:SSNLF</a>) <a href=\"http://www.recode.net/2016/10/9/13222772/samsung-galaxy-note-7-done\" target=\"_blank\">might not get another chance</a> to redeem the backfired product.</li>\n<li>AT&amp;T, T-Mobile, Sprint and Verizon began <a href=\"http://www.theverge.com/circuitbreaker/2016/10/7/13202250/att-samsung-galaxy-note-7-replacement-exchange\" target=\"_blank\">offering exchanges</a> of already replaced Note 7 devices late last week, though now these carriers (except Sprint \u2013 no news so far), are <a href=\"http://www.theverge.com/2016/10/10/13223972/verizon-samsung-galaxy-note-7-stop-sale-recall\" target=\"_blank\">terminating all sales and exchanges</a> of the smartphone.</li>\n<li>With this year's cycle looking increasingly like the iPhone's to command, the ongoing negative news involving Samsung's intended flagship Galaxy Note 7 product at a minimum has Apple (<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a> <font color=\"green\">+1.9%</font>) shares strengthening on the present term.</li>\n<li>The two companies are furthermore set to take a dispute relating to iPhone design patents before the U.S. Supreme Court tomorrow.</li>\n<li>Related: <a href=\"https://seekingalpha.com/news/3213027-google-pixel-advertising-blitz-commences\" target=\"_blank\">Google Pixel advertising blitz commences</a>\n</li>\n<li>\n<strong>Update (2:20PM ET)</strong>: Sprint <a href=\"http://www.theverge.com/circuitbreaker/2016/10/10/13228998/sprint-best-buy-galaxy-note-7-sales-stopping\" target=\"_blank\">added to list</a> of carriers ceasing distribution, Best Buy also ending sales.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213168\" data-linked=\"Apple +2%, Samsung&#39;s difficulties escalate [updated]\" data-tweet=\"$SSNLF $SSNLF $AAPL - Apple +2%, Samsung&#39;s difficulties escalate [updated] https://seekingalpha.com/news/3213168-appleplus-2-samsungs-difficulties-escalate-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3213168-appleplus-2-samsungs-difficulties-escalate-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>123&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213174\" data-ts=\"1476115253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213174-cellcom-legal-team-amps-up-action-against-golan-on-roaming-payments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom legal team amps up action against Golan on roaming payments</a></h4><ul>   <li>Cellcom Israel (<a href=\"https://seekingalpha.com/symbol/CEL\" title=\"Cellcom Israel, Ltd.\">CEL</a> <font color=\"green\">+2.8%</font>) is pushing back against actions by Golan Telecom over the two companies' roaming agreement as legal matters heat up.</li>    <li>Golan sued Cellcom, looking for a declaration that it doesn't owe Cellcom past national roaming payment differences (600M shekels plus VAT), Cellcom says, and that it intends to vigorously act to dismiss Golan's action.</li>    <li>Cellcom also says Golan informed it that Golan will pay 10.6M shekels instead of an agreed-upon 21M shekels for national roaming. Cellcom will pursue legal action to reclaim that consideration.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213174\" data-linked=\"Cellcom legal team amps up action against Golan on roaming payments\" data-tweet=\"$CEL - Cellcom legal team amps up action against Golan on roaming payments https://seekingalpha.com/news/3213174-cellcom-legal-team-amps-up-action-against-golan-on-roaming-payments?source=tweet\" data-url=\"https://seekingalpha.com/news/3213174-cellcom-legal-team-amps-up-action-against-golan-on-roaming-payments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213173\" data-ts=\"1476115242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213173-consumer-goods-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer Goods - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/PRMW\" title=\"Primo Water\">PRMW</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/FIZZ\" title=\"National Beverage Corp.\">FIZZ</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/MTOR\" title=\"Meritor, Inc.\">MTOR</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/IBA\" title=\"Industrias Bachoco, S.A.B. de C.V.\">IBA</a> <font color=\"green\">+5%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213173\" data-linked=\"Consumer Goods - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$PRMW $FIZZ $MTOR - Consumer Goods - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3213173-consumer-goods-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3213173-consumer-goods-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213177\" data-ts=\"1476114962\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTR\" target=\"_blank\">PTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213177-reuters-new-china-refinery-faces-delay-myanmar-seeks-extra-oil-tax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: New China refinery faces delay as Myanmar seeks extra oil tax</a></h4><ul>     <li>A newly built Chinese refinery near its border with Myanmar <a href=\"http://www.reuters.com/article/us-china-myanmar-oil-idUSKCN12A0JF\" target=\"_blank\">faces a delayed start-up</a> after PetroChina (<a href=\"https://seekingalpha.com/symbol/PTR\" title=\"PetroChina Company Limited\">PTR</a> <font color=\"green\">+3.1%</font>) balked at paying an extra tax for piping crude oil through the country, Reuters reports.</li>     <li>PTR parent China National Petroleum early last year began trial operations of a deep sea port and 2,400-km pipeline through Myanmar to China's Yunnan province, where CNPC also has been building a 260K bbl/day refinery at Anning to process the oil; the company completed construction of the Anning plant around July and had aimed for test operations this month, but  the project reportedly now faces delays.</li>\n<li>China has been on a diplomatic offensive in  Myanmar since the new government came to power in April,  hoping to ensure good ties with its resource-rich neighbor.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213177\" data-linked=\"Reuters: New China refinery faces delay as Myanmar seeks extra oil tax\" data-tweet=\"$PTR - Reuters: New China refinery faces delay as Myanmar seeks extra oil tax https://seekingalpha.com/news/3213177-reuters-new-china-refinery-faces-delay-myanmar-seeks-extra-oil-tax?source=tweet\" data-url=\"https://seekingalpha.com/news/3213177-reuters-new-china-refinery-faces-delay-myanmar-seeks-extra-oil-tax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213166\" data-ts=\"1476114885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPTX\" target=\"_blank\">LPTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213166-leaps-anti-dkk1-candidate-shows-positive-effect-in-early-stage-study-in-biliary-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leap&#39;s anti-DKK1 candidate shows positive effect in early-stage study in biliary cancer; marriage partner Macrocure up 36%</a></h4><ul>\n<li>Thinly traded nano cap Macrocure (MCUR <font color=\"green\">+36.4%</font>) jumps on almost a 15x surge in volume in response to merger partner Leap Therapeutics' <a href=\"http://www.leaptx.com/news/press-releases/10-08-2016/\" target=\"_blank\">announcement</a> of encouraging results from a Phase 1 clinical trial assessing lead product candidate DKN-01, in combination with chemo agents gemcitabine and cisplatin, in patients with advanced biliary cancer. The data were presented at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.</li>\n<li>In 21 evaluable patients who received a 300 mg regimen of DKN-01 plus chemo, 33% (n=7/21) were partial responders. Additionally, the disease control rate (partial responders + those with stable disease) was 95% (n=20/21). Median progression-free survival (PFS) and overall survival (OS) have yet to be reached.</li>\n<li>The combination regimen was safe and well-tolerated with no reported serious adverse events or dose-limiting toxicities.</li>\n<li>\n<a href=\"http://www.leaptx.com/science/#modulate-wnt-signaling\" target=\"_blank\">DKN-01</a> is a humanized IgG4 monoclonal antibody that binds to <a href=\"https://en.wikipedia.org/wiki/DKK1\" target=\"_blank\">Dickkopf-1</a> (DKK1), a protein associated with a poor prognosis in a range of cancers. Specifically, it inhibits a pathway called canonical Wnt/Beta-catenin which plays a key role in embryonic development, cell proliferation and differentiation.</li>\n<li>Bile duct cancer, cholangiocarcinoma, occurs in ~6K Americans each year. The five-year survival rate is less than 10% because it is usually in an advanced stage when first diagnosed.</li>\n<li>Leap and Macrocure announced their merger plans in late August.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3205836-macrocure-102-percent-merger-leap-therapeutics\" target=\"_blank\">Macrocure up 102% on merger with Leap Therapeutics</a> (Aug. 29)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213166\" data-linked=\"Leap&#39;s anti-DKK1 candidate shows positive effect in early-stage study in biliary cancer; marriage partner Macrocure up 36%\" data-tweet=\"$LPTX - Leap&#39;s anti-DKK1 candidate shows positive effect in early-stage study in biliary cancer; marriage partner Macrocure up 36% https://seekingalpha.com/news/3213166-leaps-anti-dkk1-candidate-shows-positive-effect-in-early-stage-study-in-biliary-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3213166-leaps-anti-dkk1-candidate-shows-positive-effect-in-early-stage-study-in-biliary-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213171\" data-ts=\"1476114539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213171-petrobras-busy-seeking-partners-in-asset-sale-drive-ceo-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras busy seeking partners in asset sale drive, CEO says</a></h4><ul>     <li>International oil companies <a href=\"http://www.bloomberg.com/news/articles/2016-10-10/petrobras-says-deep-water-opening-luring-big-oil-to-brazil\" target=\"_blank\">rushed to contact</a> Brazilian officials <a href=\"https://seekingalpha.com/news/3212705-brazil-votes-open-offshore-oilfields-foreign-investment\" target=\"_blank\">last week</a> after the country's congress removed a requirement that Petrobras (<a href=\"https://seekingalpha.com/symbol/PBR\" title=\"Petrobras - Petroleo Brasileiro S.A.\">PBR</a> <font color=\"green\">+3.5%</font>) control operations at all new projects in the potentially oil-rich pre-salt area, CEO Pedro Parente says.</li>     <li>Allowing others to control drilling and production in the pre-salt will provide a larger group of offshore operators for PBR to team up with at upcoming licensing rounds, and Parente says the company has a group of more than 30 projects worth ~$40B that it is marketing to potential buyers.</li>     <li>Higher than expected output at the pre-salt has cut PBR\u2019s breakeven cost to $40/bbl, and the company can lower it further, Parente says.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213171\" data-linked=\"Petrobras busy seeking partners in asset sale drive, CEO says\" data-tweet=\"$PBR - Petrobras busy seeking partners in asset sale drive, CEO says https://seekingalpha.com/news/3213171-petrobras-busy-seeking-partners-in-asset-sale-drive-ceo-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3213171-petrobras-busy-seeking-partners-in-asset-sale-drive-ceo-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213148\" data-ts=\"1476111704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213148-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> MCUR <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/MZOR' title='Mazor Robotics Ltd.'>MZOR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ZFGN' title='Zafgen, Inc.'>ZFGN</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PHMD' title='PhotoMedex, Inc.'>PHMD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-8%</font>. ITEK <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3213148\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$LPTX $TSRO $IPCI - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3213148-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3213148-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213159\" data-ts=\"1476111334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIV\" target=\"_blank\">VIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213159-telefonica-brasil-getting-new-ceo-bradesco-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telefonica Brasil getting new CEO; Bradesco downgrades</a></h4><ul>   <li>Eduardo Navarro de Carvalho is <a href=\"http://www.bloomberg.com/news/articles/2016-10-10/telefonica-changes-brazil-ceo-in-pallete-s-first-executive-move?cmpid=yhoo.hosted\" target=\"_blank\">taking over as chief executive officer</a> at Telefonica Brasil (<a href=\"https://seekingalpha.com/symbol/VIV\" title=\"Telefonica Brasil, S.A\">VIV</a> <font color=\"red\">-6.2%</font>), replacing Amos Genish, in the first major executive move since Jose Maria Alvarez-Pallete took over as Telefonica chairman (<a href=\"https://seekingalpha.com/symbol/TEF\" title=\"Telefonica S.A.\">TEF</a> <font color=\"green\">+1.4%</font>).</li>    <li>The move was apparently in the works for months, but announced earlier due to leaks from a journalist prodding about the transition.</li>    <li>Navarro is already chairman and chief commercial digital officer at Telefonica Brasil. He'll work with Genish on a transition set to complete Jan. 1.</li>    <li>Genish is leaving for personal reasons and says he won't work for another telecom \"at least for a few good years.\"</li>    <li>Analysts at Bradesco BBI downgraded shares of the stock to Neutral: \u201cOne of the main pillars of Telefonica Brasil\u2019s investment thesis, top-notch management, has weakened with Amos\u2019 resignation, increasing execution risk for synergy gains and ongoing market share gain.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213159\" data-linked=\"Telefonica Brasil getting new CEO; Bradesco downgrades\" data-tweet=\"$VIV $VIV $TEF - Telefonica Brasil getting new CEO; Bradesco downgrades https://seekingalpha.com/news/3213159-telefonica-brasil-getting-new-ceo-bradesco-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3213159-telefonica-brasil-getting-new-ceo-bradesco-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213152\" data-ts=\"1476109469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213152-npd-group-sees-4-rise-in-holiday-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NPD Group sees 4% rise in holiday spending</a></h4><ul>     <li>The NPD Group <a href=\"https://www.npd.com/wps/portal/npd/us/news/press-releases/2016/glad-tidings-for-retailers-this-holiday-season/\" target=\"_blank\">forecasts</a> holiday spending will increase 3.6% to $636 per consumer.</li>     <li>\"The unvarying holiday spending intentions expressed by consumers are a sign that even this year\u2019s intense election cycle has done little to dampen consumer confidence going into the holiday season, which we forecast to grow moderately,\" notes NPD analyst Marshal Cohen.</li>     <li>There has been some level of expectation that many retailers are going to point to election anxiety as a reason for their own disappointing earnings.</li>    <li>Previously: <a href=\"https://seekingalpha.com/news/3213064-expect-retailers-play-election-card\" target=\"_blank\">Expect retailers to play the election card</a> (Oct. 8)</li>     <li>ETFs: <a href=\"https://seekingalpha.com/symbol/XLP\" title=\"Consumer Staples Select Sector SPDR ETF\">XLP</a>, <a href=\"https://seekingalpha.com/symbol/XLY\" title=\"Consumer Discretionary Select Sector SPDR ETF\">XLY</a>, <a href=\"https://seekingalpha.com/symbol/VDC\" title=\"Vanguard Consumer Staples ETF\">VDC</a>, <a href=\"https://seekingalpha.com/symbol/XRT\" title=\"SPDR S&amp;P Retail ETF\">XRT</a>, <a href=\"https://seekingalpha.com/symbol/VCR\" title=\"Vanguard Consumer Discretionary ETF\">VCR</a>, <a href=\"https://seekingalpha.com/symbol/RTH\" title=\"VanEck Vectors Retail ETF\">RTH</a>, <a href=\"https://seekingalpha.com/symbol/RETL\" title=\"Direxion Daily Retail Bull 3x Shares ETF\">RETL</a>, <a href=\"https://seekingalpha.com/symbol/FXG\" title=\"First Trust Consumer Staples AlphaDEX ETF\">FXG</a>, <a href=\"https://seekingalpha.com/symbol/PBJ\" title=\"PowerShares Dynamic Food &amp; Beverage Portfolio ETF\">PBJ</a>, <a href=\"https://seekingalpha.com/symbol/IYK\" title=\"iShares U.S. Consumer Goods ETF\">IYK</a>, <a href=\"https://seekingalpha.com/symbol/FXD\" title=\"First Trust Consumer Discretionary AlphaDEX ETF\">FXD</a>, <a href=\"https://seekingalpha.com/symbol/IYC\" title=\"iShares U.S. Consumer Services ETF\">IYC</a>, <a href=\"https://seekingalpha.com/symbol/RHS\" title=\"Guggenheim S&amp;P Equal Weight Consumer Staples ETF\">RHS</a>, <a href=\"https://seekingalpha.com/symbol/FDIS\" title=\"Fidelity MSCI Consumer Discretionary Index ETF\">FDIS</a>, <a href=\"https://seekingalpha.com/symbol/PEJ\" title=\"PowerShares Dynamic Leisure &amp; Entertainment Portfolio ETF\">PEJ</a>, <a href=\"https://seekingalpha.com/symbol/FSTA\" title=\"Fidelity MSCI Consumer Staples Index ETF\">FSTA</a>, <a href=\"https://seekingalpha.com/symbol/PSL\" title=\"PowerShares DWA Consumer Staples Momentum Portfolio ETF\">PSL</a>, <a href=\"https://seekingalpha.com/symbol/SCC\" title=\"ProShares UltraShort Consumer Services ETF\">SCC</a>, <a href=\"https://seekingalpha.com/symbol/RCD\" title=\"Guggenheim S&amp;P Equal Weight Consumer Discretionary ETF\">RCD</a>, <a href=\"https://seekingalpha.com/symbol/UCC\" title=\"ProShares Ultra Consumer Services ETF\">UCC</a>, <a href=\"https://seekingalpha.com/symbol/PEZ\" title=\"PowerShares DWA Consumer Cyclicals Momentum Portfolio ETF\">PEZ</a>, <a href=\"https://seekingalpha.com/symbol/PMR\" title=\"PowerShares Dynamic Retail Portfolio ETF\">PMR</a>, <a href=\"https://seekingalpha.com/symbol/PSCC\" title=\"PowerShares S&amp;P SmallCap Consumer Staples Portfolio ETF\">PSCC</a>, <a href=\"https://seekingalpha.com/symbol/UGE\" title=\"ProShares Ultra Consumer Goods ETF\">UGE</a>, <a href=\"https://seekingalpha.com/symbol/PSCD\" title=\"PowerShares S&amp;P SmallCap Consumer Discretionary Portfolio ETF\">PSCD</a>, <a href=\"https://seekingalpha.com/symbol/SZK\" title=\"ProShares UltraShort Consumer Goods ETF\">SZK</a>, <a href=\"https://seekingalpha.com/symbol/BITE\" title=\"The Restaurant ETF\">BITE</a>, <a href=\"https://seekingalpha.com/symbol/CNDF\" title=\"iShares Edge MSCI Multifactor Consumer Discretionary ETF\">CNDF</a>, <a href=\"https://seekingalpha.com/symbol/CNSF\" title=\"iShares Edge MSCI Multifactor Consumer Staples ETF\">CNSF</a>, <a href=\"https://seekingalpha.com/symbol/FTXD\" title=\"First Trust Nasdaq Retail ETF\">FTXD</a>, <a href=\"https://seekingalpha.com/symbol/FTXG\" title=\"First Trust Nasdaq Food &amp; Beverage ETF\">FTXG</a>, <a href=\"https://seekingalpha.com/symbol/IBUY\" title=\"Amplify Online Retail ETF\">IBUY</a>, <a href=\"https://seekingalpha.com/symbol/JHMC\" title=\"John Hancock Multifactor Consumer Discretionary ETF\">JHMC</a>, <a href=\"https://seekingalpha.com/symbol/JHMS\" title=\"John Hancock Multifactor Consumer Staples ETF\">JHMS</a>.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3213152\" data-linked=\"NPD Group sees 4% rise in holiday spending\" data-tweet=\"$XLP $XLY $VDC - NPD Group sees 4% rise in holiday spending https://seekingalpha.com/news/3213152-npd-group-sees-4-rise-in-holiday-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/3213152-npd-group-sees-4-rise-in-holiday-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213150\" data-ts=\"1476108573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HVT\" target=\"_blank\">HVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213150-haverty-furniture-slumps-to-52-week-low-after-raymond-james-loses-faith\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Haverty Furniture slumps to 52-week low after Raymond James loses faith</a></h4><ul> <li>Shares of Haverty Furniture (<a href='https://seekingalpha.com/symbol/HVT' title='Haverty Furniture Companies Inc.'>HVT</a> <font color='red'>-11.4%</font>) turn sharply lower after Raymond James <a href=\"http://www.benzinga.com/analyst-ratings/downgrades/16/10/8545882/benzingas-top-downgrades\" target=\"_blank\">slides</a> to a Market Perform stance after having the retailer set at Strong Buy.</li> <li>Haverty carved out a new 52-week low of $16.57 before bouncing back just a bit.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3213150\" data-linked=\"Haverty Furniture slumps to 52-week low after Raymond James loses faith\" data-tweet=\"$HVT - Haverty Furniture slumps to 52-week low after Raymond James loses faith https://seekingalpha.com/news/3213150-haverty-furniture-slumps-to-52-week-low-after-raymond-james-loses-faith?source=tweet\" data-url=\"https://seekingalpha.com/news/3213150-haverty-furniture-slumps-to-52-week-low-after-raymond-james-loses-faith\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213140\" data-ts=\"1476108447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213140-bristol-myers-opdivo-fails-to-beat-chemo-first-line-treatment-in-late-stage-study-in-certain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers&#39; Opdivo fails to beat chemo as first-line treatment in late-stage study in certain type of lung cancer; shares off 9%</a></h4><ul>\n<li>Bristol-Myers Squibb (<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a> <font color=\"red\">-8.9%</font>) hits the first bump in the road with its blockbuster cancer med Opdivo (nivolumab). Results from a Phase 3 study, CheckMate-026, in treatment-naive patients with PD-L1-positive non-small cell lung cancer (NSCLC) failed to demonstrate an improvement in progression-free survival (PFS) compared to platinum-based doublet chemotherapy. The data were presented at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.</li>\n<li>Not only was there no improvement, the chemo regimen actually outperformed Opdivo in terms of median PFS: 5.9 months versus 4.2 months in patients with at least 5% PD-L1 expression. The outcome was first reported about a month ago.</li>\n<li>\n<a href=\"http://www.opdivo.bmscustomerconnect.com/gateway\" target=\"_blank\">Opdivo </a>is currently approved for the treatment of NSCLC after chemo, in addition to certain patients with Hodgkin lymphoma, renal cell carcinoma and melanoma. It was the company's top seller last quarter with $840M in sales, surpassing Eliquis ($777M) for the first time.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3200689-bristol-myers-says-lung-cancer-drug-failed-meet-primary-endpoint\" target=\"_blank\">Bristol-Myers says lung cancer drug failed to meet primary endpoint</a> (Aug. 5)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213140\" data-linked=\"Bristol-Myers&#39; Opdivo fails to beat chemo as first-line treatment in late-stage study in certain type of lung cancer; shares off 9%\" data-tweet=\"$BMY - Bristol-Myers&#39; Opdivo fails to beat chemo as first-line treatment in late-stage study in certain type of lung cancer; shares off 9% https://seekingalpha.com/news/3213140-bristol-myers-opdivo-fails-to-beat-chemo-first-line-treatment-in-late-stage-study-in-certain?source=tweet\" data-url=\"https://seekingalpha.com/news/3213140-bristol-myers-opdivo-fails-to-beat-chemo-first-line-treatment-in-late-stage-study-in-certain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>126&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213147\" data-ts=\"1476108044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213147-ebayplus-1_5-target-raised-suntrust-robinson-humphrey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ebay +1.5%, target raised at SunTrust Robinson Humphrey</a></h4><ul>\n<li>Analyst Robert Peck <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/10/8545731/suntrusts-bob-peck-has-higher-confidence-in-ebays-turnar\" target=\"_blank\">moves</a> from $30 to $33 (current price $32.08).</li>\n<li>Projects eBay's (<a href=\"https://seekingalpha.com/symbol/EBAY\" title=\"eBay Inc.\">EBAY</a> <font color=\"green\">+1.3%</font>) Q3 (to report on October 19) at $2.185B in revenue, $20.4B in GMV and EPS of $0.44.</li>\n<li>Maintains Hold rating.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213147\" data-linked=\"Ebay +1.5%, target raised at SunTrust Robinson Humphrey\" data-tweet=\"$EBAY - Ebay +1.5%, target raised at SunTrust Robinson Humphrey https://seekingalpha.com/news/3213147-ebayplus-1_5-target-raised-suntrust-robinson-humphrey?source=tweet\" data-url=\"https://seekingalpha.com/news/3213147-ebayplus-1_5-target-raised-suntrust-robinson-humphrey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213144\" data-ts=\"1476107686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRMW\" target=\"_blank\">PRMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213144-big-pop-for-primo-water-after-landing-glacier-water\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big pop for Primo Water after landing Glacier Water</a></h4><ul>          <li>Primo Water Corporation (<a href=\"https://seekingalpha.com/symbol/PRMW\" title=\"Primo Water\">PRMW</a> <font color=\"green\">+14.1%</font>) announces that it acquired Glacier Water Services Inc.</li>     <li>The company says the addition will give it 46K retail locations throughout the U.S. and Canada.</li>     <li>Primo on the deal: \"The transaction will unite two highly complementary brands and is intended to generate significant operating scale through an expansive refill and exchange network,\"</li>     <li>The combination is expected to generate approximately $6M to $7M million in annual operational and shared service synergies within 36 months of closing.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3213144\" data-linked=\"Big pop for Primo Water after landing Glacier Water\" data-tweet=\"$PRMW - Big pop for Primo Water after landing Glacier Water https://seekingalpha.com/news/3213144-big-pop-for-primo-water-after-landing-glacier-water?source=tweet\" data-url=\"https://seekingalpha.com/news/3213144-big-pop-for-primo-water-after-landing-glacier-water\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213143\" data-ts=\"1476107463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGCO\" target=\"_blank\">AGCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213143-agco-raised-wells-fargo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AGCO raised at Wells Fargo</a></h4><ul>\n<li>AGCO (<a href=\"https://seekingalpha.com/symbol/AGCO\" title=\"AGCO Corporation\">AGCO</a> <font color=\"green\">+4.6%</font>) soars in early trade after Wells Fargo <a href=\"http://www.benzinga.com/news/16/10/8545621/wells-fargo-upgrades-agco-corporation-to-outperform\" target=\"_blank\">upgraded</a> the stock to Outperform from Market Perform.</li>\n<li>\"After three years of demand decline, the company will benefit from an anticipated bottoming in global farm equipment demand. More favorable indications in Brazil and Europe should benefit approximately 70% of the company's revenue mix,\" analyst Andrew Casey said in a research note.</li>\n<li>He raised his price target range for the stock to $60-$63 from $46-$49.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213143\" data-linked=\"AGCO raised at Wells Fargo\" data-tweet=\"$AGCO - AGCO raised at Wells Fargo https://seekingalpha.com/news/3213143-agco-raised-wells-fargo?source=tweet\" data-url=\"https://seekingalpha.com/news/3213143-agco-raised-wells-fargo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213142\" data-ts=\"1476107429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRMW\" target=\"_blank\">PRMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213142-primo-water-to-buy-glacier-water-services-in-263m-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Primo Water to buy Glacier Water Services in $263M deal</a></h4><ul>     <li>Primo Water (<a href=\"https://seekingalpha.com/symbol/PRMW\" title=\"Primo Water\">PRMW</a> <font color=\"green\">+13.8%</font>) agrees to acquire Glacier Water Services for ~$263M in cash and stock, including debt.</li>     <li>PRMW says the deal unites two highly complementary brands and will generate significant operating scale through an expansive refill and exchange network, including 46K retail locations in the U.S. and Canada.</li>     <li>PRMW expects the combination to generate $6M-$7M in annual operational and shared service synergies within  36 months of closing.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213142\" data-linked=\"Primo Water to buy Glacier Water Services in $263M deal\" data-tweet=\"$PRMW - Primo Water to buy Glacier Water Services in $263M deal https://seekingalpha.com/news/3213142-primo-water-to-buy-glacier-water-services-in-263m-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3213142-primo-water-to-buy-glacier-water-services-in-263m-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213137\" data-ts=\"1476106062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAA\" target=\"_blank\">UAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213137-under-armour-on-watch-after-wells-turns-positive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour on watch after Wells turns positive</a></h4><ul> <li>Under Armour (NYSE:<a href=\"https://seekingalpha.com/symbol/UA\" title=\"Under Armour, Inc. Class C\">UA</a>) is racing higher in early trading with a positive note out from Wells Fargo.</li> <li>Wells move to an Outperform rating from Market Perform.</li>  <li>Investor looking to do their own analysis can check out the <a href=\"https://drive.google.com/file/d/0B2uMe9ZWiyJCc1FMeFJmMmVkZWc/view\" target=\"_blank\">Excel model</a> created by SA contributor Alexander Valtsev that allows assumptions to be tested.</li>\n<li>UA <font color=\"green\">+1.91%</font> premarket to $38.50. Under Armour hasn't closed over $40 since late August.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213137\" data-linked=\"Under Armour on watch after Wells turns positive\" data-tweet=\"$UAA - Under Armour on watch after Wells turns positive https://seekingalpha.com/news/3213137-under-armour-on-watch-after-wells-turns-positive?source=tweet\" data-url=\"https://seekingalpha.com/news/3213137-under-armour-on-watch-after-wells-turns-positive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213128\" data-ts=\"1476105939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213128-late-stage-study-shows-tesaros-niraparib-benefits-ovarian-cancer-patients-regardless-of-brca\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Late-stage study shows TESARO&#39;s niraparib benefits ovarian cancer patients regardless of BRCA status; shares ahead 15% premarket</a></h4><ul>\n<li>TESARO (NASDAQ:<a href=\"https://seekingalpha.com/symbol/TSRO\" title=\"Tesaro\">TSRO</a>) is up <font color=\"green\">15%</font> premarket on increased volume in response to its announcement of positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/show/NCT01847274\" target=\"_blank\">ENGOT-OV16/NOVA</a>, assessing PARP inhibitor niraparib in ovarian cancer (OC) patients. The data were presented at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.</li>\n<li>ENGOT-OV16/NOVA met its primary endpoint of showing that treatment with niraparib extended progression-free survival (PFS) in both BRCA-positive and BRCA-negative OC patients.</li>\n<li>Median PFS for the BRCA-positive arm was 21.0 months compared to 5.5 months for control (p&lt;0.0001). In addition, patients experienced a 55% reduction in the risk of death or cancer progression (hazard ratio: 0.45). In the BRCA-negative cohort, median PFS was 9.3 months versus 3.9 months for control (p&lt;0.0001) with the same 0.45 hazard ratio.</li>\n<li>The most common serious (grade 3 or 4) treatment-emergent adverse events for niraparib were thrombocytopenia (33.8%), anemia (25.3%) and neutropenia (19.6%).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213128\" data-linked=\"Late-stage study shows TESARO&#39;s niraparib benefits ovarian cancer patients regardless of BRCA status; shares ahead 15% premarket\" data-tweet=\"$TSRO - Late-stage study shows TESARO&#39;s niraparib benefits ovarian cancer patients regardless of BRCA status; shares ahead 15% premarket https://seekingalpha.com/news/3213128-late-stage-study-shows-tesaros-niraparib-benefits-ovarian-cancer-patients-regardless-of-brca?source=tweet\" data-url=\"https://seekingalpha.com/news/3213128-late-stage-study-shows-tesaros-niraparib-benefits-ovarian-cancer-patients-regardless-of-brca\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213136\" data-ts=\"1476105386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213136-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGAS' title='Gas Natural Inc.'>EGAS</a> <font color='green'>+69%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CRNT' title='Ceragon Networks Ltd.'>CRNT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MZOR' title='Mazor Robotics Ltd.'>MZOR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='green'>+6%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DOV' title='Dover Corp'>DOV</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213136\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$EGAS $IPCI $TSRO - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3213136-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3213136-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213135\" data-ts=\"1476105357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213135-american-eagle-outfitters-on-watch-after-bmo-capital-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Eagle Outfitters on watch after BMO Capital nod</a></h4><ul> <li>BMO Capital <a href=\"http://www.streetinsider.com/Upgrades/BMO+Capital+Upgrades+American+Eagle+Outfitters+%28AEO%29+to+Outperform/12116985.html\" target=\"_blank\">upgrades</a> American Eagle Outfitters (NYSE:<a href=\"https://seekingalpha.com/symbol/AEO\" title=\"American Eagle Outfitters, Inc.\">AEO</a>) to Outperform from Market Perform.</li> <li>The investment firm assigns a price target of $21 on the retailer.</li> <li>Shares of AEO are <font color=\"green\">up 2.18%</font> premarket to $17.85 on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213135\" data-linked=\"American Eagle Outfitters on watch after BMO Capital nod\" data-tweet=\"$AEO - American Eagle Outfitters on watch after BMO Capital nod https://seekingalpha.com/news/3213135-american-eagle-outfitters-on-watch-after-bmo-capital-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3213135-american-eagle-outfitters-on-watch-after-bmo-capital-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213125\" data-ts=\"1476104197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213125-twitterminus-13_55-pre-market-salesforce-bid-reported-unlikely\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter -13.55% pre-market, Salesforce bid reported unlikely</a></h4><ul>\n<li>Alphabet, The Walt Disney Co. and others had <a href=\"https://seekingalpha.com/news/3212720-twitter-sale-deadline-now-question-timeline-reportedly-unchanged\" target=\"_blank\">already been considered</a> ruled out from the list of interested parties at one point contemplating a possible acquisition of Twitter (NYSE:<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a>).</li>\n<li>Over the weekend, a <a href=\"https://www.bloomberg.com/news/articles/2016-10-08/twitter-sales-process-said-almost-dead-as-suitors-lose-interest\" target=\"_blank\">Bloomberg report</a> noted Salesforce (NYSE:<a href=\"https://seekingalpha.com/symbol/CRM\" title=\"Salesforce.com, Inc.\">CRM</a>), once thought to be seriously involved in the situation, is additionally not expected to pursue a deal.</li>\n<li>Salesforce shares <a href=\"https://seekingalpha.com/news/3212522-salesforce-shares-record-steepest-decline-yet-reignited-twitter-interest-reports-minus-7\" target=\"_blank\">have been pressured</a> by the rumors in recent weeks, though are <font color=\"green\">up 3%</font> in pre-market trading as its interest is now supposedly fading.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213125\" data-linked=\"Twitter -13.55% pre-market, Salesforce bid reported unlikely\" data-tweet=\"$TWTR $TWTR $CRM - Twitter -13.55% pre-market, Salesforce bid reported unlikely https://seekingalpha.com/news/3213125-twitterminus-13_55-pre-market-salesforce-bid-reported-unlikely?source=tweet\" data-url=\"https://seekingalpha.com/news/3213125-twitterminus-13_55-pre-market-salesforce-bid-reported-unlikely\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213124\" data-ts=\"1476104093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPTT\" target=\"_blank\">OPTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213124-ocean-power-tech-to-launch-2_5m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocean Power Tech to launch 2.5M-share offering</a></h4><ul>     <li>Ocean Power Technologies (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OPTT\" title=\"Ocean Power Technologies, Inc.\">OPTT</a>) <font color=\"red\">-15.1%</font> premarket after announcing a 2.5M-share public offering, with an underwriters option to purchase up to an additional 375K shares.</li>     <li>OPTT says it plans to use the proceeds for general  corporate purposes, which may include additional development and  demonstrations of its PowerBuoy system to raise its commercialization efforts and expand its sales and marketing functions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213124\" data-linked=\"Ocean Power Tech to launch 2.5M-share offering\" data-tweet=\"$OPTT - Ocean Power Tech to launch 2.5M-share offering https://seekingalpha.com/news/3213124-ocean-power-tech-to-launch-2_5m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3213124-ocean-power-tech-to-launch-2_5m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213122\" data-ts=\"1476103999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213122-netflix-lower-after-deutsche-bank-warns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix lower after Deutsche Bank warns</a></h4><ul> <li>Deutsche Bank <a href=\"http://www.cnbc.com/2016/10/10/early-movers-myl-db-via-cbs-twtr-mrk-baba-utx-mcd-more.html\" target=\"_blank\">issues</a> a Sell rating on Netflix (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NFLX\" title=\"Netflix, Inc.\">NFLX</a>) on what it sees as an unfavorable risk-reward profile after the recent runup in share price (+9% in two weeks).</li> <li>The investment firm thinks the market is setting expectations too high for the next four years.</li> <li>NFLX <font color=\"red\">-1.49%</font> premarket to $103.26.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3213122\" data-linked=\"Netflix lower after Deutsche Bank warns\" data-tweet=\"$NFLX - Netflix lower after Deutsche Bank warns https://seekingalpha.com/news/3213122-netflix-lower-after-deutsche-bank-warns?source=tweet\" data-url=\"https://seekingalpha.com/news/3213122-netflix-lower-after-deutsche-bank-warns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213119\" data-ts=\"1476103638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213119-mazor-receives-orders-for-25-systems-in-q3-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mazor receives orders for 25 systems in Q3; shares ahead 8% premarket</a></h4><ul>\n<li>Thinly traded micro cap Mazor Robotics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MZOR\" title=\"Mazor Robotics Ltd.\">MZOR</a>) is up <font color=\"green\">8%</font> premarket on modest volume in response to its announcement that it received 25 purchase orders for its systems in Q3, including three pre-launch orders for its new Mazor X guidance system and 15 orders from strategic partner Medtronic (NYSE:<a href=\"https://seekingalpha.com/symbol/MDT\" title=\"Medtronic plc\">MDT</a>).</li>\n<li>At the end of Q3, Mazor's installed base of Renaissance systems was 131 globally, including 79 in the U.S.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213119\" data-linked=\"Mazor receives orders for 25 systems in Q3; shares ahead 8% premarket\" data-tweet=\"$MDT $MZOR $MDT - Mazor receives orders for 25 systems in Q3; shares ahead 8% premarket https://seekingalpha.com/news/3213119-mazor-receives-orders-for-25-systems-in-q3-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3213119-mazor-receives-orders-for-25-systems-in-q3-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213115\" data-ts=\"1476102436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FANG\" target=\"_blank\">FANG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213115-diamondback-energy-lifts-2016-production-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diamondback Energy lifts 2016 production guidance</a></h4><ul>     <li>Diamondback Energy (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FANG\" title=\"Diamondback Energy\">FANG</a>) <font color=\"green\">+4%</font> premarket after raising its 2016 production guidance, offering preliminary 2017 production guidance and saying it is no longer pursuing talks on an acquisition.</li>     <li>FANG says it is increasing its 2016 production guidance to 41K-42K boe/day, +6% from the midpoint of its July guidance range of 38K-40K boe/day, citing continued strong well performance, and plans to complete 65-70 gross horizontal wells this year; 2016 capex guidance is unchanged at $350M-$425M.</li>     <li>FANG's preliminary FY 2017 production guidance is 52K-58K boe/day, with the midpoint more than 30% higher than the midpoint of updated 2016 production  guidance.</li>     <li>Average daily production during Q3 was 44.9K boe/day (73% oil), +22% from Q2's 36.8K boe/day.</li>     <li>FANG also confirms it had been in talks for an acquisition but that it is no longer actively pursuing further negotiations; <a href=\"https://seekingalpha.com/news/3211888-wsj-diamondback-energy-near-deal-buy-silver-hill-2_5b\" target=\"_blank\">earlier reports</a> had said FANG was near a deal to buy Silver Hill Energy Partners.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3213115\" data-linked=\"Diamondback Energy lifts 2016 production guidance\" data-tweet=\"$FANG - Diamondback Energy lifts 2016 production guidance https://seekingalpha.com/news/3213115-diamondback-energy-lifts-2016-production-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3213115-diamondback-energy-lifts-2016-production-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213107\" data-ts=\"1476101991\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDX\" target=\"_blank\">CLDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213107-celldexs-glembatumumab-vedotin-successful-in-mid-stage-melanoma-study-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celldex&#39;s glembatumumab vedotin successful in mid-stage melanoma study; shares ahead 5% premarket</a></h4><ul>\n<li>Celldex Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLDX\" title=\"Celldex Therapeutics, Inc\">CLDX</a>) is up <font color=\"green\">5%</font> premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing antibody-drug conjugate glembatumumab vedotin in advanced treatment-resistant melanoma. The data were presented at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.</li>\n<li>The objective response rate (ORR) was 11% (n=7/62) and the median duration of response was 6.0 months (heavily pretreated population). The disease control rate (responders + those with stable disease for at least three months) was 52% (n=32/62) as was the proportion of patients experiencing tumor shrinkage. Median progression-free survival (PFS) was 4.4 months.</li>\n<li>The company has amended the protocol of the study to add a second cohort of patients who will be treated with a combination of glembatumumab vedotin and varlilumab. After enrollment is completed, a new arm will be explored assessing a combination of glembatumumab vedotin and an immune checkpoint inhibitor.</li>\n<li>\n<a href=\"http://www.celldex.com/pipeline/cdx-011.php\" target=\"_blank\">Glembatumumab vedotin</a> is fully human antibody-drug conjugate that links a glycoprotein NMB (gpNMB)-targeting antibody called CR011 to a potent cytotoxic agent called monomethyl auristatin E. GpNMB is overexpressed in multiple tumor types, including more than 80% of metastatic melanoma cases. It is also being evaluated in triple negative breast cancer and osteosarcoma (bone cancer).</li>\n<li>\n<a href=\"http://www.celldex.com/pipeline/cdx-1127.php\" target=\"_blank\">Varlilumab </a>(CDX-1127) is a fully human monoclonal antibody that targets <a href=\"http://en.wikipedia.org/wiki/CD27\" target=\"_blank\">CD27</a>, a member of the tumor necrosis factor receptor class. It plays a key role in the activation pathway of lymphocytes and can be effectively manipulated with activating antibodies to induce potent anti-tumor effects while being less toxic due to its restricted expression and regulation.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213107\" data-linked=\"Celldex&#39;s glembatumumab vedotin successful in mid-stage melanoma study; shares ahead 5% premarket\" data-tweet=\"$CLDX - Celldex&#39;s glembatumumab vedotin successful in mid-stage melanoma study; shares ahead 5% premarket https://seekingalpha.com/news/3213107-celldexs-glembatumumab-vedotin-successful-in-mid-stage-melanoma-study-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3213107-celldexs-glembatumumab-vedotin-successful-in-mid-stage-melanoma-study-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213106\" data-ts=\"1476101382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213106-alnylams-late-stage-study-of-patisiran-in-hereditary-attr-amyloidosis-to-continue-planned\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam&#39;s late-stage study of patisiran in hereditary ATTR amyloidosis to continue as planned; shares up 2% premarket</a></h4><ul>\n<li>Alnylam       Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ALNY\" title=\"Alnylam Pharmaceuticals, Inc.\">ALNY</a>) announces that the Data Monitoring Committee (DMC) for its Phase 3 APOLLO study of patisiran in patients with hereditary <a href=\"http://emedicine.medscape.com/article/335301-overview#a1\" target=\"_blank\">ATTR       amyloidosis</a> with <a href=\"https://en.wikipedia.org/wiki/Polyneuropathy\" target=\"_blank\">polyneuropathy</a> (hATTR-PN) met on October 7 and       recommended continuation of the trial without modification. The APOLLO       DMC met at the request of the Company following the decision announced       on October 5 to discontinue development of revusiran for the       treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM).       The DMC will continue to meet periodically per their remit to monitor       the overall safety of patisiran in APOLLO through its       completion. Top-line data are expected in mid-2017.</li>\n<li>ATTR amyloidosis is a progressively debilitating and often fatal disease       caused by deposition of transthyretin (TTR) in peripheral tissues. TTR       protein is produced primarily in the liver and is normally a carrier of       vitamin A. In hereditary ATTR amyloidosis (hATTR), mutations in TTR       cause abnormal amyloid proteins to accumulate and damage body organs and       tissue, such as the peripheral nerves and heart, resulting in       intractable peripheral sensory neuropathy, autonomic neuropathy, and/or       cardiomyopathy.</li>\n<li>Shares are up <font color=\"green\">2%</font> premarket, but only on turnover of 457.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213106\" data-linked=\"Alnylam&#39;s late-stage study of patisiran in hereditary ATTR amyloidosis to continue as planned; shares up 2% premarket\" data-tweet=\"$ALNY - Alnylam&#39;s late-stage study of patisiran in hereditary ATTR amyloidosis to continue as planned; shares up 2% premarket https://seekingalpha.com/news/3213106-alnylams-late-stage-study-of-patisiran-in-hereditary-attr-amyloidosis-to-continue-planned?source=tweet\" data-url=\"https://seekingalpha.com/news/3213106-alnylams-late-stage-study-of-patisiran-in-hereditary-attr-amyloidosis-to-continue-planned\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213108\" data-ts=\"1476100776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGAS\" target=\"_blank\">EGAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213108-gas-natural-to-be-bought-first-reserve-for-13_10-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gas Natural to be bought by First Reserve for $13.10/share</a></h4><ul>\n<li>Gas Natural (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/EGAS\" title=\"Gas Natural Inc.\">EGAS</a>) <font color=\"green\">+69%</font> premarket after saying it agreed to be acquired by P-E firm First Reserve for ~$196M in cash, or $13.10/share, a 71% premium to Friday's $7.68 closing price.</li>\n<li>EGAS says there will be no changes to its organization or operates, and its current dividend will be maintained.</li>\n<li>The deal, which includes a 42-day \"go shop\" period until Nov. 22, is subject to approvals of public utilities commissions of Maine, Montana, North Carolina and Ohio, as well as EGAS shareholders.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213108\" data-linked=\"Gas Natural to be bought by First Reserve for $13.10/share\" data-tweet=\"$EGAS - Gas Natural to be bought by First Reserve for $13.10/share https://seekingalpha.com/news/3213108-gas-natural-to-be-bought-first-reserve-for-13_10-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3213108-gas-natural-to-be-bought-first-reserve-for-13_10-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213105\" data-ts=\"1476100666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213105-deere-raised-wells-fargo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deere raised at Wells Fargo</a></h4><ul>\n<li>Deere (NYSE:<a href=\"https://seekingalpha.com/symbol/DE\" title=\"Deere &amp; Company\">DE</a>) <font color=\"green\">+1.7%</font> premarket after Wells Fargo <a href=\"http://www.streetinsider.com/Upgrades/Wells+Fargo+Upgrades+Deere+to+Outperform/12116903.html\" target=\"_blank\">upgraded</a> the stock to Outperform from Market Perform.</li>\n<li>DE shares are <font color=\"green\">up 13.2%</font> since the beginning of the year.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213105\" data-linked=\"Deere raised at Wells Fargo\" data-tweet=\"$DE - Deere raised at Wells Fargo https://seekingalpha.com/news/3213105-deere-raised-wells-fargo?source=tweet\" data-url=\"https://seekingalpha.com/news/3213105-deere-raised-wells-fargo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3213099\" data-ts=\"1476099972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3213099-exelixis-cabometyx-beats-pfizers-sutent-in-mid-stage-kidney-cancer-study-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis&#39; Cabometyx beats Pfizer&#39;s Sutent in mid-stage kidney cancer study; shares up 8% premarket</a></h4><ul>\n<li>Exelixis (NASDAQ:<a href=\"https://seekingalpha.com/symbol/EXEL\" title=\"Exelixis, Inc.\">EXEL</a>) is up <font color=\"green\">8%</font> premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01835158?term=cabozantinib&amp;cond=renal+cell+carcinoma&amp;phase=1&amp;rank=2\" target=\"_blank\">CABOSUN</a>, assessing CABOMETYX (cabozantinib) compared to Pfizer's (NYSE:<a href=\"https://seekingalpha.com/symbol/PFE\" title=\"Pfizer Inc.\">PFE</a>) SUTENT (sunitinib malate) in treatment-naive patients with advanced renal cell carcinoma (RCC). The data were presented at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.</li>\n<li>With a median follow-up period of 20.8 months, patients treated with cabozantinib experienced 31% less risk of death or cancer progression (hazard ratio: 0.69) than those treated with sunitinib. Median progression-free survival (PFS) in the cabozantinib cohort was 8.2 months versus 5.6 months for sunitinib. Median overall survival (OS) also favored cabozantinib (30.3 months vs. 21.8 months) as did the objective response rate (ORR) (46% vs. 18%).</li>\n<li>Exelixis plans to submit a supplement New Drug Application (sNDA) with the FDA as soon as feasible.</li>\n<li>\n<a href=\"https://hcp.cabometyx.com/?gclid=COzjnuae0M8CFQULaQodE9YEZg\" target=\"_blank\">CABOMETYX </a>is currently approved in the U.S. for the treatment of RCC. <a href=\"http://www.sutent.com/\" target=\"_blank\">SUTENT </a>is approved in the U.S. for treating gastrointestinal stromal tumors, RCC and pancreatic neuroendocrine tumors.</li>\n<li>The company and commercialization partner Ipsen will host a conference call today at 1:00 pm ET to discuss the data.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3213099\" data-linked=\"Exelixis&#39; Cabometyx beats Pfizer&#39;s Sutent in mid-stage kidney cancer study; shares up 8% premarket\" data-tweet=\"$EXEL $EXEL $PFE - Exelixis&#39; Cabometyx beats Pfizer&#39;s Sutent in mid-stage kidney cancer study; shares up 8% premarket https://seekingalpha.com/news/3213099-exelixis-cabometyx-beats-pfizers-sutent-in-mid-stage-kidney-cancer-study-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3213099-exelixis-cabometyx-beats-pfizers-sutent-in-mid-stage-kidney-cancer-study-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":49,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}